| Year |
Citation |
Score |
| 2024 |
Izadmehr S, Fernandez-Hernandez H, Wiredja D, Kirschenbaum A, Lee-Poturalski C, Tavassoli P, Yao S, Schlatzer D, Hoon D, Difeo A, Levine AC, Mosquera JM, Galsky MD, Cordon-Cardo C, Narla G. Cooperativity of c-MYC with Krüppel-Like Factor 6 Splice Variant 1 induces phenotypic plasticity and promotes prostate cancer progression and metastasis. Biorxiv : the Preprint Server For Biology. PMID 38352401 DOI: 10.1101/2024.01.30.577982 |
0.326 |
|
| 2023 |
Rasool RU, O'Connor CM, Das CK, Alhusayan M, Verma BK, Islam S, Frohner IE, Deng Q, Mitchell-Velasquez E, Sangodkar J, Ahmed A, Linauer S, Mudrak I, Rainey J, Zawacki KP, ... ... Narla G, et al. Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance. Nature Communications. 14: 5253. PMID 37644036 DOI: 10.1038/s41467-023-40760-6 |
0.739 |
|
| 2023 |
Peris I, Romero-Murillo S, Vicente C, Narla G, Odero MD. Regulation and role of the PP2A-B56 holoenzyme family in cancer. Biochimica Et Biophysica Acta. Reviews On Cancer. 1878: 188953. PMID 37437699 DOI: 10.1016/j.bbcan.2023.188953 |
0.385 |
|
| 2023 |
Avelar RA, Armstrong AJ, Carvette G, Gupta R, Puleo N, Colina JA, Joseph P, Sobeck AM, O'Connor CM, Raines B, Gandhi A, Dziubinski ML, Ma DS, Resnick K, Singh S, ... ... Narla G, et al. Small molecule mediated stabilization of PP2A modulates the Homologous Recombination pathway and potentiates DNA damage-induced cell death. Molecular Cancer Therapeutics. PMID 36788429 DOI: 10.1158/1535-7163.MCT-21-0880 |
0.389 |
|
| 2022 |
Shatat MA, Gauthier B, Yoon S, Yuan E, Yang P, Narla G, Dowlati A, Lee RT. Mistletoe lectin inhibits growth of Myc-amplified small-cell lung cancer. Cancer Medicine. PMID 36562288 DOI: 10.1002/cam4.5558 |
0.374 |
|
| 2022 |
Peris I, Romero-Murillo S, Martínez-Balsalobre E, Farrington CC, Arriazu E, Marcotegui N, Jiménez-Muñoz M, Alburquerque-Prieto C, Torres-López A, Fresquet VJ, Martinez-Climent JA, Mateos MC, Cayuela ML, Narla G, Odero MD, et al. Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation. Blood. PMID 36455198 DOI: 10.1182/blood.2022016466 |
0.352 |
|
| 2022 |
Haanen TJ, O'Connor CM, Narla G. Biased holoenzyme assembly of Protein Phosphatase 2A (PP2A): from cancer to small molecules. The Journal of Biological Chemistry. 102656. PMID 36328247 DOI: 10.1016/j.jbc.2022.102656 |
0.44 |
|
| 2021 |
O'Connor CM, Taylor SE, Miller KM, Hurst L, Haanen TJ, Suhan TK, Zawacki KP, Noto FK, Trako J, Mohan A, Sangodkar J, Zamarin D, DiFeo A, Narla G. Targeting ribonucleotide reductase induces synthetic lethality in PP2A-deficient uterine serous carcinoma. Cancer Research. PMID 34921012 DOI: 10.1158/0008-5472.CAN-21-1987 |
0.731 |
|
| 2021 |
Brautigan DL, Farrington C, Narla G. Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents. Clinical Science (London, England : 1979). 135: 1545-1556. PMID 34192314 DOI: 10.1042/CS20201367 |
0.476 |
|
| 2021 |
Laine A, Nagelli SG, Farrington C, Butt U, Cvrljevic AN, Vainonen JP, Feringa FM, Grönroos TJ, Gautam P, Khan S, Sihto H, Qiao X, Pavic K, Connolly DC, Kronqvist P, ... ... Narla G, et al. CIP2A interacts with TopBP1 and drives basal-like breast cancer tumorigenesis. Cancer Research. PMID 34145035 DOI: 10.1158/0008-5472.CAN-20-3651 |
0.315 |
|
| 2021 |
Kaemmer CA, Umesalma S, Maharjan CK, Moose DL, Narla G, Mott SL, Zamba GKD, Breheny P, Darbro BW, Bellizzi AM, Henry MD, Quelle DE. Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis. Scientific Reports. 11: 10252. PMID 33986468 DOI: 10.1038/s41598-021-89866-1 |
0.331 |
|
| 2021 |
Scarpa M, Singh P, Bailey CM, Lee JK, Kapoor S, Lapidus RG, Niyongere S, Sangodkar J, Wang Y, Perrotti D, Narla G, Baer MR. PP2A-activating drugs enhance FLT3 inhibitor efficacy through AKT inhibition-dependent GSK-3β-mediated c-Myc and Pim-1 proteasomal degradation. Molecular Cancer Therapeutics. PMID 33568357 DOI: 10.1158/1535-7163.MCT-20-0663 |
0.717 |
|
| 2020 |
Noto FK, Sangodkar J, Adedeji BT, Moody S, McClain CB, Tong M, Ostertag E, Crawford J, Gao X, Hurst L, O'Connor CM, Hanson EN, Izadmehr S, Tohmé R, Narla J, ... ... Narla G, et al. The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies. Plos One. 15: e0240169. PMID 33027304 DOI: 10.1371/journal.pone.0240169 |
0.716 |
|
| 2020 |
Merisaari J, Denisova OV, Doroszko M, Le Joncour V, Johansson P, Leenders WPJ, Kastrinsky DB, Zaware N, Narla G, Laakkonen P, Nelander S, Ohlmeyer M, Westermarck J. Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma. Brain Communications. 2: fcaa002. PMID 32954276 DOI: 10.1093/braincomms/fcaa002 |
0.32 |
|
| 2020 |
Tian D, Tang J, Geng X, Li Q, Wang F, Zhao H, Narla G, Yao X, Zhang Y. Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy. Cancer Letters. PMID 32814087 DOI: 10.1016/J.Canlet.2020.08.008 |
0.472 |
|
| 2020 |
Coles GL, Cristea S, Webber JT, Levin RS, Moss SM, He A, Sangodkar J, Hwang YC, Arand J, Drainas AP, Mooney NA, Demeter J, Spradlin JN, Mauch B, Le V, ... ... Narla G, et al. Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells. Cancer Cell. PMID 32531271 DOI: 10.1016/J.Ccell.2020.05.003 |
0.768 |
|
| 2020 |
Qiu Z, Fa P, Liu T, Prasad CB, Ma S, Hong Z, Chan ER, Wang H, Li Z, He K, Wang QE, Williams TM, Yan C, Sizemore ST, Narla G, et al. A genome-wide pooled shRNA screen identifies PPP2R2A as a predictive biomarker for the response to ATR and CHK1 inhibitors. Cancer Research. PMID 32522823 DOI: 10.1158/0008-5472.Can-20-0057 |
0.424 |
|
| 2020 |
O'Connor CM, Narla G. Splice of Life for Cancer: Missplicing of PPP2R5A by Mutant SF3B1 Leads to MYC Stabilization and Tumorigenesis. Cancer Discovery. 10: 765-767. PMID 32482664 DOI: 10.1158/2159-8290.Cd-20-0358 |
0.462 |
|
| 2020 |
Leonard D, Huang W, Izadmehr S, O'Connor CM, Wiredja DD, Wang Z, Zaware N, Chen Y, Schlatzer DM, Kiselar J, Vasireddi N, Schüchner S, Perl AL, Galsky MD, Xu W, ... ... Narla G, et al. Selective PP2A Enhancement through Biased Heterotrimer Stabilization. Cell. PMID 32315618 DOI: 10.1016/J.Cell.2020.03.038 |
0.401 |
|
| 2020 |
Mazhar S, Leonard D, Sosa A, Schlatzer D, Thomas D, Narla G. Challenges and Reinterpretation of Antibody-Based Research on Phosphorylation of Tyr on PP2Ac. Cell Reports. 30: 3164-3170.e3. PMID 32130915 DOI: 10.1016/J.Celrep.2020.02.012 |
0.306 |
|
| 2020 |
Adedeji BT, Fallon NK, Moody S, Steffey V, Brenzel C, Crawford J, Jamling TY, Narla G. Abstract 6133: Rats support cancer studies Cancer Research. 80: 6133-6133. DOI: 10.1158/1538-7445.Am2020-6133 |
0.463 |
|
| 2019 |
Farrington CC, Yuan E, Mazhar S, Izadmehr S, Hurst L, Allen-Petersen BL, Janghorban M, Chung E, Wolczanski G, Galsky M, Sears R, Sangodkar J, Narla G. Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers. The Journal of Biological Chemistry. PMID 31822503 DOI: 10.1074/Jbc.Ra119.011443 |
0.802 |
|
| 2019 |
Risom T, Wang X, Liang J, Zhang X, Pelz C, Campbell LG, Eng J, Chin K, Farrington C, Narla G, Langer EM, Sun XX, Su Y, Daniel CJ, Dai MS, et al. Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity. The Journal of Clinical Investigation. PMID 31763993 DOI: 10.1172/Jci126390 |
0.482 |
|
| 2019 |
Perl AL, O'Connor CM, Fa P, Mayca Pozo F, Zhang J, Zhang Y, Narla G. Protein phosphatase 2A controls ongoing DNA replication by binding to and regulating cell division cycle 45 (CDC45). The Journal of Biological Chemistry. PMID 31562245 DOI: 10.1074/Jbc.Ra119.010432 |
0.326 |
|
| 2019 |
O'Connor CM, Leonard D, Wiredja D, Avelar RA, Wang Z, Schlatzer D, Bryson B, Tokala E, Taylor SE, Upadhyay A, Sangodkar J, Gingras AC, Westermarck J, Xu W, DiFeo A, ... ... Narla G, et al. Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. Oncogene. PMID 31541192 DOI: 10.1038/S41388-019-1012-2 |
0.748 |
|
| 2019 |
Rasool RU, Natesan R, Deng Q, Aras S, Lal P, Sander Effron S, Mitchell-Velasquez E, Posimo JM, Carskadon S, Baca SC, Pomerantz MM, Siddiqui J, Schwartz LE, Lee DJ, Palanisamy N, ... Narla G, et al. CDK7 inhibition suppresses Castration-Resistant Prostate Cancer through MED1 inactivation. Cancer Discovery. PMID 31466944 DOI: 10.1158/2159-8290.Cd-19-0189 |
0.446 |
|
| 2019 |
Perrotti D, Agarwal A, Lucas CM, Narla G, Neviani P, Odero MD, Ruvolo PP, Verrills NM. Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia". Science Translational Medicine. 11. PMID 31316003 DOI: 10.1126/Scitranslmed.Aau0416 |
0.406 |
|
| 2019 |
Parasido E, Avetian G, Naeem A, Graham G, Pishvaian M, Glasgow E, Mudambi S, Lee Y, Ihemelandu C, Choudhry M, Peran I, Banerjee PP, Avantaggiati ML, Bryant K, Baldelli E, ... ... Narla G, et al. The sustained induction of c-Myc drives nab-paclitaxel resistance in primary pancreatic ductal carcinoma cells. Molecular Cancer Research : McR. PMID 31164413 DOI: 10.1158/1541-7786.Mcr-19-0191 |
0.381 |
|
| 2019 |
Taylor SE, O'Connor CM, Wang Z, Shen G, Song H, Leonard D, Sangodkar J, LaVasseur C, Avril S, Waggoner S, Zanotti K, Armstrong AJ, Nagel C, Resnick K, Singh S, ... ... Narla G, et al. The highly recurrent PP2A Aα-subunit mutation P179R alters protein structure and impairs PP2A enzyme function to promote endometrial tumorigenesis. Cancer Research. PMID 31142515 DOI: 10.1158/0008-5472.Can-19-0218 |
0.732 |
|
| 2019 |
Yang P, Jiang Y, Pan Y, Ding X, Rhea P, Ding J, Hawke DH, Felsher D, Narla G, Lu Z, Lee RT. Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression. Scientific Reports. 9: 6428. PMID 31015523 DOI: 10.1038/S41598-019-41444-2 |
0.364 |
|
| 2019 |
Farrington CC, Narla G. Lulling the Cancer Cell into an Eternal Sleep. Cancer Research. 79: 1756-1757. PMID 30987978 DOI: 10.1158/0008-5472.Can-19-0853 |
0.47 |
|
| 2019 |
Tohmé R, Izadmehr S, Gandhe S, Tabaro G, Vallabhaneni S, Thomas A, Vasireddi N, Dhawan NS, Ma'ayan A, Sharma N, Galsky MD, Ohlmeyer M, Sangodkar J, Narla G. Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma. Jci Insight. 4. PMID 30830869 DOI: 10.1172/Jci.Insight.125693 |
0.763 |
|
| 2019 |
O'Connor CM, Hoffa MT, Taylor SE, Avelar RA, Narla G. Protein phosphatase 2A Aα regulates Aβ protein expression and stability. The Journal of Biological Chemistry. PMID 30796164 DOI: 10.1074/Jbc.Ra119.007593 |
0.48 |
|
| 2019 |
Umesalma S, Kaemmer CA, Kohlmeyer JL, Letney BL, Schab AM, Reilly JA, Sheehy RM, Hagen J, Tiwari N, Zhan F, Leidinger MR, O'Dorisio TM, Dillon JS, Merrill RA, Meyerholz DK, ... ... Narla G, et al. RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth. The Journal of Clinical Investigation. PMID 30721156 DOI: 10.1172/Jci123049 |
0.504 |
|
| 2019 |
Mazhar S, Taylor SE, Sangodkar J, Narla G. Targeting PP2A in cancer: Combination therapies. Biochimica Et Biophysica Acta. Molecular Cell Research. 1866: 51-63. PMID 30401535 DOI: 10.1016/J.Bbamcr.2018.08.020 |
0.787 |
|
| 2019 |
Scarpa M, Singh P, Kapoor S, Lee JK, Niyongere S, Narla G, Perrotti D, Baer MR. PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation Blood. 134: 1276-1276. DOI: 10.1182/Blood-2019-129011 |
0.43 |
|
| 2019 |
Parasido EM, Avetian GS, Brody J, Winter J, Londin E, Pishvaian M, Glasgow E, Byers S, Narla G, Albanese C. Abstract 1283: Targeting c-MYC and MAPK pathway to overcome pancreatic cancer drug resistance Cancer Research. 79: 1283-1283. DOI: 10.1158/1538-7445.Am2019-1283 |
0.422 |
|
| 2019 |
Noto FK, Adedeji BT, Moody S, Brenzel C, Crawford J, Narla G, Evers BM, Jamling TY. Abstract B067: A Rag2/Il2rg double-knockout rat (SRG OncoRat) enables precision-medicine based cancer studies with cell line- and patient-derived xenografts Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B067 |
0.443 |
|
| 2019 |
Rasool R, Natesan R, deng q, Aras S, Lal P, Posimo J, Palanisamy N, Narla G, Den R, Freedman M, brady d, asangani ia. Abstract B016: CDK7 inhibition suppresses AR addicted Castration-Resistant Prostate Cancer through MED1 inactivation Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B016 |
0.493 |
|
| 2018 |
Allen-Petersen BL, Risom T, Feng Z, Wang Z, Jenny ZP, Thoma MC, Pelz KR, Morton JP, Sansom OJ, Lopez CD, Sheppard B, Christensen DJ, Ohlmeyer M, Narla G, Sears RC. Activation of PP2A and inhibition of mTOR synergistically reduce MYC signaling and decrease tumor growth in pancreatic ductal adenocarcinoma. Cancer Research. PMID 30389701 DOI: 10.1158/0008-5472.Can-18-0717 |
0.503 |
|
| 2018 |
Noto FK, Adjan Steffey V, Tong M, Ravichandran K, Zhang W, Arey A, McClain CB, Ostertag E, Mazhar S, Sangodkar J, Difeo A, Crawford J, Narla G, Jamling TY. Sprague Dawley Rag2 null rats created from engineered spermatogonial stem cells are immunodeficient and permissive to human xenografts. Molecular Cancer Therapeutics. PMID 30206106 DOI: 10.1158/1535-7163.Mct-18-0156 |
0.735 |
|
| 2018 |
Kauko O, O'Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, Haapaniemi P, Momeny M, Varila T, Ohlmeyer M, Aittokallio T, ... ... Narla G, et al. PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Science Translational Medicine. 10. PMID 30021885 DOI: 10.1126/Scitranslmed.Aaq1093 |
0.79 |
|
| 2018 |
Narla G, Sangodkar J, Ryder CB. The impact of phosphatases on proliferative and survival signaling in cancer. Cellular and Molecular Life Sciences : Cmls. PMID 29725697 DOI: 10.1007/S00018-018-2826-8 |
0.752 |
|
| 2018 |
McClinch K, A Avelar R, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, ... ... Narla G, et al. Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer. Cancer Research. PMID 29358171 DOI: 10.1158/0008-5472.Can-17-0123 |
0.771 |
|
| 2018 |
Jayappa KD, Portell CA, Gordon VL, Narla G, Bender TP, Williams ME, Weber MJ. Drug Combinations Co-Targeting Myeloid Cell Leukemia-1 (Mcl-1) Protein Can Overcome Microenvironmentally-Induced Multi-Drug Tolerance in Non-Hodgkin Lymphomas Blood. 132: 2649-2649. DOI: 10.1182/Blood-2018-99-116759 |
0.393 |
|
| 2018 |
Noto FK, Ravi K, Arey A, McClain C, Zhang W, Narla G, Crawford J, Yeshi T. Abstract B36: Novel immunodeficient rat models capable of supporting the growth of human tumor xenografts Cancer Research. 78. DOI: 10.1158/1538-7445.Mousemodels17-B36 |
0.463 |
|
| 2018 |
Wiredja DD, Liao P, Sangodkar J, Schlatzer D, Chance MR, Narla G. Abstract 2698: Phosphoproteomics-guided anticancer drug combination design with a novel small-molecule PP2A activator Cancer Research. 78: 2698-2698. DOI: 10.1158/1538-7445.Am2018-2698 |
0.768 |
|
| 2018 |
Tohme R, Sangodkar J, Dhawan N, Izadmeher S, Sharma N, Ohlmeyer M, Narla G. Abstract 1827: Direct activation of the tumor suppressor protein phosphatase 2A as a therapeutic strategy for TKI-resistant lung adenocarcinoma Cancer Research. 78: 1827-1827. DOI: 10.1158/1538-7445.Am2018-1827 |
0.534 |
|
| 2018 |
Noto FK, Towobola B, Arey A, Narla G, Chengelis C, Yeshi T. Abstract 1155: The SRGTM rat: A novel SCID rat for humanization studies Cancer Research. 78: 1155-1155. DOI: 10.1158/1538-7445.Am2018-1155 |
0.391 |
|
| 2018 |
Ravi K, Noto F, McClain C, Arey A, Narla G, Crawford J, Yeshi T. Abstract B170: Novel immunodeficient rat models offer a unique platform for drug efficacy studies in human tumor xenografts Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B170 |
0.463 |
|
| 2017 |
O'Connor CM, Perl A, Leonard D, Sangodkar J, Narla G. Therapeutic Targeting of PP2A. The International Journal of Biochemistry & Cell Biology. PMID 29107183 DOI: 10.1016/J.Biocel.2017.10.008 |
0.745 |
|
| 2017 |
Wiredja DD, Ayati M, Mazhar S, Sangodkar J, Maxwell S, Schlatzer D, Narla G, Koyutürk M, Chance MR. Phosphoproteomics Profiling of Non-Small Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator. Proteomics. PMID 28961369 DOI: 10.1002/Pmic.201700214 |
0.773 |
|
| 2017 |
Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, Izadmehr S, Mazhar S, Wiredja DD, O'Connor CM, Hoon D, Dhawan NS, Schlatzer D, Yao S, Leonard D, ... ... Narla G, et al. Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. The Journal of Clinical Investigation. PMID 28504649 DOI: 10.1172/Jci89548 |
0.81 |
|
| 2017 |
Ryder CB, Narla G. Direct-Acting Small Molecule Activators of PP2A (SMAPs) in Myeloid Malignancies: Understanding Mechanisms of Cytotoxicity to Inform Rational Combinatorial Therapeutic Strategies Blood. 130: 2517-2517. DOI: 10.1182/Blood.V130.Suppl_1.2517.2517 |
0.455 |
|
| 2017 |
Tohme R, Sangodkar J, Kiselar J, Leonard D, O'Connor C, Gandhe S, Xu W, Brautigan D, Chance M, Ohlmeyer M, Narla G. Abstract 4173: Drug target mutations as a mechanism of acquired resistance to small molecules activators of protein phosphatase 2a Cancer Research. 77: 4173-4173. DOI: 10.1158/1538-7445.Am2017-4173 |
0.713 |
|
| 2017 |
Armstrong A, Joseph P, Nagaraj A, Nagel C, Nakayama J, Waggoner S, Zanotti K, DiFeo A, Narla G. The use of novel PP2A activators in combination withPARP inhibitor for the treatment of high-grade serous ovarian cancer Gynecologic Oncology. 145: 73. DOI: 10.1016/J.Ygyno.2017.03.173 |
0.451 |
|
| 2016 |
Sangodkar J, Tohme R, Kiselar J, Izadmehr S, Hoon D, Mazhar S, Perl A, Wiredja D, Schlatzer D, Yao S, Kastrinsky D, Sharma N, Brautigan D, Chance M, Borczuk A, ... ... Narla G, et al. Abstract 3865: Therapeutic activation of protein phosphatase 2A for the treatment of lung cancer Cancer Research. 76: 3865-3865. DOI: 10.1158/1538-7445.Am2016-3865 |
0.816 |
|
| 2016 |
Farrington CC, Wang X, Janghorban M, Liang J, Difeo A, Sears R, Narla G. Abstract 3857: Pharmacological reactivation of the tumor suppressor protein phosphatase 2A as a novel approach for the treatment of breast cancer Cancer Research. 76: 3857-3857. DOI: 10.1158/1538-7445.Am2016-3857 |
0.555 |
|
| 2015 |
Kastrinsky DB, Sangodkar J, Zaware N, McClinch K, Farrington CC, Giannini HM, Izadmehr S, Dhawan NS, Narla G, Ohlmeyer M. Corrigendum to "Reengineered tricyclic anti-cancer agents" [Bioorg. Med. Chem. 23 (2015) 6528-6534]. Bioorganic & Medicinal Chemistry. 23: 7487. PMID 28290285 DOI: 10.1016/J.Bmc.2015.11.002 |
0.727 |
|
| 2015 |
Sangodkar J, Farrington C, McClinch K, Galsky MD, Kastrinsky DB, Narla G. All roads lead to PP2A: Exploiting the therapeutic potential of this phosphatase. The Febs Journal. PMID 26507691 DOI: 10.1111/Febs.13573 |
0.768 |
|
| 2015 |
Kastrinsky DB, Sangodkar J, Zaware N, Izadmehr S, Dhawan NS, Narla G, Ohlmeyer M. Reengineered tricyclic anti-cancer agents. Bioorganic & Medicinal Chemistry. 23: 6528-34. PMID 26372073 DOI: 10.1016/J.Bmc.2015.07.007 |
0.76 |
|
| 2015 |
Wolpaw BJ, Narla G, Cheemalavagu S. Abstract B49: Using small molecule activators of PP2A to negatively regulate c-myc in small cell lung cancer Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-B49 |
0.497 |
|
| 2015 |
Allen-Petersen BL, Farrell AS, Jenny ZP, Daniel CJ, Wang Z, Lopez CD, Christensen DJ, Narla G, Sheppard BC, Sears RC. Abstract B21: Protein phosphatase 2A (PP2A) activation functions synergistically with kinase inhibition in pancreatic cancer Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-B21 |
0.56 |
|
| 2015 |
Brubaker D, Elena S, Smith K, Monroe M, Ryu C, Chance MR, Narla G, Bebek G. Abstract PR04: Cancer drug response networks built for comparative cancer pharmacogenomics identifies combination therapies for repositioning Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-Pr04 |
0.457 |
|
| 2015 |
Wang X, Farrell A, Janghorban M, Allen-Petersen B, Liang J, Risom T, Ohlmeyer M, Narla G, Sears RC. Abstract SY38-03: Targeting post-translational activation of MYC for the treatment of cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Sy38-03 |
0.447 |
|
| 2015 |
Sangodkar J, Izadmehr S, Mahzar S, Hoon D, Yao S, Kastrinsky D, Schlatzer D, Sharma N, Borczuk AC, Ohlmeyer M, Ioannou Y, Narla G. Abstract 5329: Development of small molecule activators of protein phosphatase 2A for the treatment of lung cancer Cancer Research. 75: 5329-5329. DOI: 10.1158/1538-7445.Am2015-5329 |
0.814 |
|
| 2015 |
McClinch K, Avelar R, Callejas D, Kastrinsky D, Ohlmeyer M, Plymate S, Galsky M, Narla G. Abstract C132: Therapeutic reactivation of PP2A for prostate cancer treatment Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C132 |
0.542 |
|
| 2015 |
Sangodkar J, McQuaid D, Kisselar J, Brautigan D, Chance M, Ohlmeyer M, Kastrinsky D, Ioannou Y, Narla G. Abstract B124: Drugging the undruggable: development of small molecule activators of protein phosphatase 2A for cancer treatment Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B124 |
0.821 |
|
| 2015 |
Singh S, Joseph P, Nagaraj A, Armstrong A, Resnick K, Zanotti K, Waggoner S, Narla G, DiFeo A. Small molecule activators of protein phosphatase 2A for the treatment of endometrial cancer Gynecologic Oncology. 137: 208. DOI: 10.1016/J.Ygyno.2015.01.523 |
0.468 |
|
| 2014 |
Yuen T, Stachnik A, Iqbal J, Sgobba M, Gupta Y, Lu P, Colaianni G, Ji Y, Zhu LL, Kim SM, Li J, Liu P, Izadmehr S, Sangodkar J, Bailey J, ... ... Narla G, et al. Bisphosphonates inactivate human EGFRs to exert antitumor actions. Proceedings of the National Academy of Sciences of the United States of America. 111: 17989-94. PMID 25453081 DOI: 10.1073/Pnas.1421410111 |
0.791 |
|
| 2014 |
Stachnik A, Yuen T, Iqbal J, Sgobba M, Gupta Y, Lu P, Colaianni G, Ji Y, Zhu LL, Kim SM, Li J, Liu P, Izadmehr S, Sangodkar J, Scherer T, ... ... Narla G, et al. Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 111: 17995-8000. PMID 25453078 DOI: 10.1073/Pnas.1421422111 |
0.794 |
|
| 2014 |
Martin BN, Wang C, Willette-Brown J, Herjan T, Gulen MF, Zhou H, Bulek K, Franchi L, Sato T, Alnemri ES, Narla G, Zhong XP, Thomas J, Klinman D, Fitzgerald KA, et al. IKKα negatively regulates ASC-dependent inflammasome activation. Nature Communications. 5: 4977. PMID 25266676 DOI: 10.1038/Ncomms5977 |
0.331 |
|
| 2014 |
Dermawan JK, Gurova K, Pink J, Dowlati A, De S, Narla G, Sharma N, Stark GR. Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer. Molecular Cancer Therapeutics. 13: 2203-14. PMID 25028470 DOI: 10.1158/1535-7163.Mct-14-0013 |
0.514 |
|
| 2014 |
Parikh A, Lee C, Joseph P, Marchini S, Baccarini A, Kolev V, Romualdi C, Fruscio R, Shah H, Wang F, Mullokandov G, Fishman D, D'Incalci M, Rahaman J, Kalir T, ... ... Narla G, et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nature Communications. 5: 2977. PMID 24394555 DOI: 10.1038/Ncomms3977 |
0.412 |
|
| 2014 |
Dermawan JKT, Pink J, Dowlati A, De S, Narla G, Stark GR, Sharma N. Enhanced antitumor activity of erlotinib in combination with quinacrine in EGFR WT and L858R/T790M mutant NSCLC. Journal of Clinical Oncology. 32: e22153-e22153. DOI: 10.1200/Jco.2014.32.15_Suppl.E22153 |
0.422 |
|
| 2014 |
Sangodkar J, Mazhar S, Wiredja D, Gokulrangan G, Schlatzer D, Kastrinsky D, Difeo A, Yao S, Izadmehr S, Sharma N, Ioannou Y, Ohlmeyer M, Narla G. Abstract A38: Therapeutic targeting of oncogenic KRAS signaling using a novel small molecule agonist of the PP2A tumor suppressor gene Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-A38 |
0.817 |
|
| 2014 |
Wiredja D, Liu Y, Schlatzer D, Gokulrangan G, Narla G, Chance M. Abstract 1616: Phosphoprotein enrichment pathway analysis tools for studying cancer signaling Cancer Research. 74: 1616-1616. DOI: 10.1158/1538-7445.Am2014-1616 |
0.485 |
|
| 2014 |
Narla G. Are Two Heads Really Better than One? Science Translational Medicine. 6: 227ec46-227ec46. DOI: 10.1126/Scitranslmed.3008863 |
0.533 |
|
| 2014 |
Narla G. Shiva the Destroyer: Targeting the Destruction of RNA Polymerase for Cancer Treatment Science Translational Medicine. 6: 221ec21-221ec21. DOI: 10.1126/Scitranslmed.3008473 |
0.441 |
|
| 2014 |
McClinch K, Callejas D, Cooper M, Stachnik A, Kastrinsky D, Ohlmeyer M, Galsky M, Narla G. 548 Development of a small molecule activator of protein phosphatase 2A for the treatment of prostate cancer European Journal of Cancer. 50: 178. DOI: 10.1016/S0959-8049(14)70674-4 |
0.464 |
|
| 2014 |
Sangodkar J, Mazhar S, Kastrinsky D, Ohlmeyer M, Narla G. 486 Development of small molecule activators of protein phosphatase 2A for the treatment of lung cancer European Journal of Cancer. 50: 158-159. DOI: 10.1016/S0959-8049(14)70612-4 |
0.745 |
|
| 2013 |
Hatami R, Sieuwerts AM, Izadmehr S, Yao Z, Qiao RF, Papa L, Look MP, Smid M, Ohlssen J, Levine AC, Germain D, Burstein D, Kirschenbaum A, DiFeo A, Foekens JA, ... Narla G, et al. KLF6-SV1 drives breast cancer metastasis and is associated with poor survival. Science Translational Medicine. 5: 169ra12. PMID 23345610 DOI: 10.1126/Scitranslmed.3004688 |
0.807 |
|
| 2013 |
Das TK, Sangodkar J, Negre N, Narla G, Cagan RL. Sin3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors. Oncogene. 32: 3184-97. PMID 22890320 DOI: 10.1038/Onc.2012.326 |
0.76 |
|
| 2013 |
Dermawan JKT, Gurova K, Pink J, Dowlati A, De S, Narla G, Sharma N, Stark G. Abstract A263: Combination of quinacrine and erlotinib overcomes resistance to erlotinib in non-small cell lung cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A263 |
0.521 |
|
| 2013 |
Parikh A, Lee C, Joseph P, Marchini S, Baccarini A, Kolev V, Romualdi C, Fruscio R, Shah H, Feng W, Mullokandov G, Fishman D, D'Incalci M, Rahaman J, Kalir T, ... ... Narla G, et al. Abstract B47: microRNA-181a plays a critical role in ovarian cancer progression through the regulation of epithelial-mesenchymal transition Clinical Cancer Research. 19: 47-47. DOI: 10.1158/1078-0432.Ovca13-B47 |
0.483 |
|
| 2013 |
Narla G. A new kid on the block Science Translational Medicine. 5. DOI: 10.1126/Scitranslmed.3008080 |
0.566 |
|
| 2013 |
Narla G. Out with the New, In with the Old Science Translational Medicine. 5: 209ec179-209ec179. DOI: 10.1126/Scitranslmed.3007775 |
0.487 |
|
| 2013 |
Narla G. A New Achilles Heel for Prostate Cancer Science Translational Medicine. 5: 203ec155-203ec155. DOI: 10.1126/Scitranslmed.3007556 |
0.482 |
|
| 2013 |
Narla G. Drugging the Undruggable Science Translational Medicine. 5. DOI: 10.1126/Scitranslmed.3007131 |
0.433 |
|
| 2013 |
Narla G. Bringing Down the House by Targeting the Scaffold Science Translational Medicine. 5. DOI: 10.1126/Scitranslmed.3006521 |
0.499 |
|
| 2012 |
Sangodkar J, Dhawan NS, Melville H, Singh VJ, Yuan E, Rana H, Izadmehr S, Farrington C, Mazhar S, Katz S, Albano T, Arnovitz P, Okrent R, Ohlmeyer M, Galsky M, ... ... Narla G, et al. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. The Journal of Clinical Investigation. 122: 2637-51. PMID 22653055 DOI: 10.1172/Jci62058 |
0.765 |
|
| 2012 |
Vetter D, Cohen-Naftaly M, Villanueva A, Lee YA, Kocabayoglu P, Hannivoort R, Narla G, M Llovet J, Thung SN, Friedman SL. Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. Hepatology (Baltimore, Md.). 56: 1361-70. PMID 22535637 DOI: 10.1002/Hep.25810 |
0.348 |
|
| 2012 |
Izadmehr S, Lee CH, Fernandez H, Hatami R, Kirschenbaum A, Levine AC, Difeo A, Narla G. Abstract A57: Functional synergy between the KLF6-SV1 and c-MYC oncogenes in driving prostate cancer metastasis in a novel mouse model of the disease Cancer Research. 72: A57-A57. DOI: 10.1158/1538-7445.Prca2012-A57 |
0.806 |
|
| 2012 |
Hatami R, Ohlseen J, Izadmehr S, Sieuwerts AM, Papa L, Kirschenbaum A, Levine A, Germain D, Foekens JA, DiFeo A, Narla G. Abstract 5314: An oncogenic splice variant of the KLF6 tumor suppressor gene is associated with poor survival and is a potent driver of breast cancer metastasis Cancer Research. 72: 5314-5314. DOI: 10.1158/1538-7445.Am2012-5314 |
0.819 |
|
| 2012 |
Sangodkar J, Dhawan N, Melville H, Singh VJ, Farrington C, Yuan E, Rana H, Smith B, Gidwani V, Okrent R, Burstein D, Ohlmeyer M, Politi K, DiFeo A, Narla G. Abstract 1885: Targeting the FOXO1/KLF6 transcriptional network to modulate response to anti-EGFR based therapy Cancer Research. 72: 1885-1885. DOI: 10.1158/1538-7445.Am2012-1885 |
0.784 |
|
| 2011 |
Tarocchi M, Hannivoort R, Hoshida Y, Lee UE, Vetter D, Narla G, Villanueva A, Oren M, Llovet JM, Friedman SL. Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology (Baltimore, Md.). 54: 522-31. PMID 21563203 DOI: 10.1002/Hep.24413 |
0.34 |
|
| 2011 |
Sangodkar J, Katz S, Melville H, Singh V, Dhawan N, DiFeo A, Narla G. Abstract 2899: Restoring sensitivity to anti-EGFR-based therapy in lung adenocarcinoma by downstream modulation of the FOXO1/KLF6 transcriptional network Cancer Research. 71: 2899-2899. DOI: 10.1158/1538-7445.Am2011-2899 |
0.79 |
|
| 2011 |
Dhawan N, Smith B, Sangodkar J, Gidwani V, Kastrinsky D, Ohlmeyer M, Narla G. Abstract A218: Simultaneous inhibition of both the PI3K-AKT and MAPK-ERK pathways using a single small molecule based approach for the treatment of advanced cancer. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A218 |
0.774 |
|
| 2011 |
Fishman D, Wang F, DiFeo A, Narla G. Quantitative PCR array identification of microRNA clusters associated with epithelial ovarian cancer chemoresistance Gynecologic Oncology. 120: S54. DOI: 10.1016/J.Ygyno.2010.12.131 |
0.353 |
|
| 2010 |
Sangodkar J, Katz S, Melville H, Narla G. Lung adenocarcinoma: lessons in translation from bench to bedside. The Mount Sinai Journal of Medicine, New York. 77: 597-605. PMID 21105123 DOI: 10.1002/Msj.20226 |
0.77 |
|
| 2010 |
Tchirkov A, Sapin V, Marceau G, Chautard E, Narla G, Veronese L, Friedman S, Khalil T, Vago P, Kemeny JL, Verrelle P. Increased expression of the oncogenic KLF6-SV1 transcript in human glioblastoma. Clinical Chemistry and Laboratory Medicine. 48: 1167-70. PMID 20545576 DOI: 10.1515/Cclm.2010.219 |
0.351 |
|
| 2010 |
Lee UE, Ghiassi-Nejad Z, Paris AJ, Yea S, Narla G, Walsh M, Friedman SL. Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG1 oncogene. Febs Letters. 584: 1006-10. PMID 20116377 DOI: 10.1016/J.Febslet.2010.01.049 |
0.369 |
|
| 2010 |
Sangodkar J, Katz S, Albano T, Melville H, Burstein D, Politi K, Difeo A, Narla G. Abstract B41: Restoring sensitivity to anti-EGFR-based therapy in lung adenocarcinoma by downstream modulation of the FOXO1/KLF6 transcriptional network Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-B41 |
0.771 |
|
| 2009 |
DiFeo A, Narla G, Martignetti JA. Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment. The Mount Sinai Journal of Medicine, New York. 76: 557-66. PMID 20014424 DOI: 10.1002/Msj.20150 |
0.524 |
|
| 2009 |
Difeo A, Huang F, Sangodkar J, Terzo EA, Leake D, Narla G, Martignetti JA. KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model. Cancer Research. 69: 4733-41. PMID 19435908 DOI: 10.1158/0008-5472.Can-08-4282 |
0.763 |
|
| 2009 |
Xiong SD, Yu K, Liu XH, Yin LH, Kirschenbaum A, Yao S, Narla G, DiFeo A, Wu JB, Yuan Y, Ho SM, Lam YW, Levine AC. Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. International Journal of Cancer. 125: 774-82. PMID 19384952 DOI: 10.1002/Ijc.24325 |
0.436 |
|
| 2009 |
Sangodkar J, DiFeo A, Feld L, Bromberg R, Schwartz R, Huang F, Terzo EA, Choudhri A, Narla G. Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma. Lung Cancer (Amsterdam, Netherlands). 66: 292-7. PMID 19328586 DOI: 10.1016/J.Lungcan.2009.02.014 |
0.78 |
|
| 2009 |
Sangodkar J, Shi J, DiFeo A, Schwartz R, Bromberg R, Choudhri A, McClinch K, Hatami R, Scheer E, Kremer-Tal S, Martignetti JA, Hui A, Leung WK, Friedman SL, Narla G. Functional role of the KLF6 tumour suppressor gene in gastric cancer. European Journal of Cancer (Oxford, England : 1990). 45: 666-76. PMID 19101139 DOI: 10.1016/J.Ejca.2008.11.009 |
0.796 |
|
| 2009 |
DiFeo A, Martignetti JA, Narla G. The role of KLF6 and its splice variants in cancer therapy. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 12: 1-7. PMID 19097929 DOI: 10.1016/J.Drup.2008.11.001 |
0.547 |
|
| 2009 |
Xiong SD, Yu K, Liu XH, Yin LH, Kirschenbaum A, Yao S, Narla G, DiFeo A, Wu JB, Yuan Y, Ho SM, Lam YW, Levine AC. Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells (International Journal of Cancer (2009) 125, (774-782)) International Journal of Cancer. 125: 1995. DOI: 10.1002/Ijc.24691 |
0.449 |
|
| 2008 |
Hartel M, Narla G, Wente MN, Giese NA, Martignoni ME, Martignetti JA, Friess H, Friedman SL. Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer. European Journal of Cancer (Oxford, England : 1990). 44: 1895-903. PMID 18691883 DOI: 10.1016/J.Ejca.2008.06.030 |
0.425 |
|
| 2008 |
Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, Hod E, Leake D, Friedman SL, Hall SJ, Chinnaiyan AM, Gerald WL, Rubin MA, Martignetti JA. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. The Journal of Clinical Investigation. 118: 2711-21. PMID 18596922 DOI: 10.1172/Jci34780 |
0.756 |
|
| 2008 |
Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, Villanueva A, Loke J, Tarocchi M, Akita K, Shirasawa S, Sasazuki T, Martignetti JA, Llovet JM, Friedman SL. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology. 134: 1521-31. PMID 18471523 DOI: 10.1053/J.Gastro.2008.02.015 |
0.426 |
|
| 2008 |
DiFeo A, Feld L, Rodriguez E, Wang C, Beer DG, Martignetti JA, Narla G. A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response. Cancer Research. 68: 965-70. PMID 18250346 DOI: 10.1158/0008-5472.Can-07-2604 |
0.524 |
|
| 2008 |
Bentov I, Narla G, Schayek H, Akita K, Plymate SR, LeRoith D, Friedman SL, Werner H. Insulin-like growth factor-i regulates Kruppel-like factor-6 gene expression in a p53-dependent manner. Endocrinology. 149: 1890-7. PMID 18174288 DOI: 10.1210/En.2007-0844 |
0.445 |
|
| 2007 |
Teixeira MS, Camacho-Vanegas O, Fernandez Y, Narla G, DiFeo A, Lee B, Kalir T, Friedman SL, Schlecht NF, Genden EM, Urken M, Brandwein-Gensler M, Martignetti JA. KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma. International Journal of Cancer. 121: 1976-83. PMID 17621627 DOI: 10.1002/Ijc.22926 |
0.455 |
|
| 2007 |
Camacho-Vanegas O, Narla G, Teixeira MS, DiFeo A, Misra A, Singh G, Chan AM, Friedman SL, Feuerstein BG, Martignetti JA. Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. International Journal of Cancer. Journal International Du Cancer. 121: 1390-5. PMID 17514651 DOI: 10.1002/Ijc.22809 |
0.465 |
|
| 2007 |
Narla G, Kremer-Tal S, Matsumoto N, Zhao X, Yao S, Kelley K, Tarocchi M, Friedman SL. In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma. Oncogene. 26: 4428-34. PMID 17297474 DOI: 10.1038/Sj.Onc.1210223 |
0.425 |
|
| 2007 |
Kremer-Tal S, Narla G, Chen Y, Hod E, DiFeo A, Yea S, Lee JS, Schwartz M, Thung SN, Fiel IM, Banck M, Zimran E, Thorgeirsson SS, Mazzaferro V, Bruix J, et al. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. Journal of Hepatology. 46: 645-54. PMID 17196295 DOI: 10.1016/J.Jhep.2006.10.012 |
0.319 |
|
| 2006 |
Banck MS, Beaven SW, Narla G, Walsh MJ, Friedman SL, Beutler AS. KLF6 degradation after apoptotic DNA damage. Febs Letters. 580: 6981-6. PMID 17113081 DOI: 10.1016/J.Febslet.2006.10.077 |
0.397 |
|
| 2006 |
DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL, Kalir T, Yao S, Levine A, Birrer MJ, Bonome T, Friedman SL, Buller RE, Martignetti JA. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3730-9. PMID 16778100 DOI: 10.1158/1078-0432.Ccr-06-0054 |
0.476 |
|
| 2006 |
DiFeo A, Narla G, Camacho-Vanegas O, Nishio H, Rose SL, Buller RE, Friedman SL, Walsh MJ, Martignetti JA. E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene. 25: 6026-31. PMID 16702959 DOI: 10.1038/Sj.Onc.1209611 |
0.392 |
|
| 2006 |
Kirschenbaum A, Liu XH, Yao S, Narla G, Friedman SL, Martignetti JA, Levine AC. Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral versus transition zones. Carcinogenesis. 27: 216-24. PMID 16123118 DOI: 10.1093/Carcin/Bgi219 |
0.387 |
|
| 2005 |
Park JH, Eliyahu E, Narla G, DiFeo A, Martignetti JA, Schuchman EH. KLF6 is one transcription factor involved in regulating acid ceramidase gene expression Biochimica Et Biophysica Acta - Gene Structure and Expression. 1732: 82-87. PMID 16500425 DOI: 10.1016/J.Bbaexp.2006.01.002 |
0.363 |
|
| 2005 |
Li D, Yea S, Dolios G, Martignetti JA, Narla G, Wang R, Walsh MJ, Friedman SL. Regulation of Kruppel-like factor 6 tumor suppressor activity by acetylation. Cancer Research. 65: 9216-25. PMID 16230382 DOI: 10.1158/0008-5472.Can-05-1040 |
0.448 |
|
| 2005 |
Narla G, DiFeo A, Yao S, Banno A, Hod E, Reeves HL, Qiao RF, Camacho-Vanegas O, Levine A, Kirschenbaum A, Chan AM, Friedman SL, Martignetti JA. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Research. 65: 5761-8. PMID 15994951 DOI: 10.1158/0008-5472.Can-05-0217 |
0.501 |
|
| 2005 |
Li D, Yea S, Li S, Chen Z, Narla G, Banck M, Laborda J, Tan S, Friedman JM, Friedman SL, Walsh MJ. Krüppel-like factor-6 promotes preadipocyte differentiation through histone deacetylase 3-dependent repression of DLK1. The Journal of Biological Chemistry. 280: 26941-52. PMID 15917248 DOI: 10.1074/Jbc.M500463200 |
0.358 |
|
| 2005 |
Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, Katz A, Isaacs WB, Hebbring S, Komiya A, McDonnell SK, Wiley KE, Jacobsen SJ, Isaacs SD, Walsh PC, et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Research. 65: 1213-22. PMID 15735005 DOI: 10.1158/0008-5472.Can-04-4249 |
0.461 |
|
| 2004 |
Kremer-Tal S, Reeves HL, Narla G, Thung SN, Schwartz M, Difeo A, Katz A, Bruix J, Bioulac-Sage P, Martignetti JA, Friedman SL. Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (Baltimore, Md.). 40: 1047-52. PMID 15486921 DOI: 10.1002/Hep.20460 |
0.35 |
|
| 2004 |
Benzeno S, Narla G, Allina J, Cheng GZ, Reeves HL, Banck MS, Odin JA, Diehl JA, Germain D, Friedman SL. Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Research. 64: 3885-91. PMID 15172998 DOI: 10.1158/0008-5472.Can-03-2818 |
0.418 |
|
| 2004 |
Rubinstein M, Idelman G, Plymate SR, Narla G, Friedman SL, Werner H. Transcriptional activation of the insulin-like growth factor I receptor gene by the Kruppel-like factor 6 (KLF6) tumor suppressor protein: potential interactions between KLF6 and p53. Endocrinology. 145: 3769-77. PMID 15131018 DOI: 10.1210/En.2004-0173 |
0.378 |
|
| 2004 |
Kimmelman AC, Qiao RF, Narla G, Banno A, Lau N, Bos PD, Nuñez Rodriguez N, Liang BC, Guha A, Martignetti JA, Friedman SL, Chan AM. Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. Oncogene. 23: 5077-83. PMID 15064720 DOI: 10.1038/Sj.Onc.1207662 |
0.454 |
|
| 2004 |
Reeves HL, Narla G, Ogunbiyi O, Haq AI, Katz A, Benzeno S, Hod E, Harpaz N, Goldberg S, Tal-Kremer S, Eng FJ, Arthur MJ, Martignetti JA, Friedman SL. Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology. 126: 1090-103. PMID 15057748 DOI: 10.1053/J.Gastro.2004.01.005 |
0.464 |
|
| 2003 |
Dowling O, Difeo A, Ramirez MC, Tukel T, Narla G, Bonafe L, Kayserili H, Yuksel-Apak M, Paller AS, Norton K, Teebi AS, Grum-Tokars V, Martin GS, Davis GE, Glucksman MJ, et al. Mutations in capillary morphogenesis gene-2 result in the allelic disorders juvenile hyaline fibromatosis and infantile systemic hyalinosis. American Journal of Human Genetics. 73: 957-66. PMID 12973667 DOI: 10.1086/378781 |
0.329 |
|
| 2003 |
Narla G, Friedman SL, Martignetti JA. Krüppel cripples prostate cancer: KLF6 progress and prospects. The American Journal of Pathology. 162: 1047-52. PMID 12651597 DOI: 10.1016/S0002-9440(10)63901-6 |
0.408 |
|
| 2003 |
Hirshfeld J, Narla G, Difeo A, Kalir T, Buller R, Friedman S, Martignetti J. KLF6 POLYMORPHISM IN PROSTATE CANCER REVEALS A NOVEL MECHANISM OF TUMOR SUPPRESSOR GENE INACTIVATION. Journal of Investigative Medicine. 51: 336.2-337. DOI: 10.1136/Jim-51-06-21 |
0.427 |
|
| 2003 |
REEVES H, ARTHUR M, NARLA G, KATZ A, FRIEDMAN S. 51 Novel growth suppressor targets of the KLF6 tumor suppressor gene identified by stringent microarray analysis Hepatology. 38: 179-179. DOI: 10.1016/S0270-9139(03)80094-0 |
0.364 |
|
| 2001 |
Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, Glucksman MJ, Narla J, Eng FJ, Chan AM, Ferrari AC, Martignetti JA, Friedman SL. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science (New York, N.Y.). 294: 2563-6. PMID 11752579 DOI: 10.1126/Science.1066326 |
0.445 |
|
| Show low-probability matches. |